Detailed Mechanism Funding and Narrative

Years of mechanism: 2014 2015 2016 2017 2018 2019

Details for Mechanism ID: 17274
Country/Region: Botswana
Year: 2018
Main Partner: University of Maryland
Main Partner Program: NA
Organizational Type: University
Funding Agency: HHS/CDC
Total Funding: $8,666,897 Additional Pipeline Funding: N/A

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $0
Care: Orphans and Vulnerable Children (HKID) $0
Care: TB/HIV (HVTB) $300,000
Care: Pediatric Care and Support (PDCS) $54,000
Laboratory Infrastructure (HLAB) $0
Strategic Information (HVSI) $0
Health Systems Strengthening (OHSS) $0
Biomedical Prevention: Voluntary Medical Male Circumcision (CIRC) $0
Biomedical Prevention: Blood Safety (HMBL) $0
Biomedical Prevention: Injection Safety (HMIN) $0
Sexual Prevention: Abstinence/Be Faithful (HVAB) $0
Testing: HIV Testing and Counseling (HVCT) $0
Sexual Prevention: Other Sexual Prevention (HVOP) $500,000
Prevention: Injecting and Non-Injecting Drug Use (IDUP) $0
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $450,000
Treatment: ARV Drugs (HTXD) $0
Treatment: Adult Treatment (HTXS) $6,638,897
Treatment: Pediatric Treatment (PDTX) $724,000
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
PMTCT_ART Already on ART at beginning of current pregnancy 2019 2,955
PMTCT_ART New on ART 2019 1,145
PMTCT_ART Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy 2019 4,100
PMTCT_ART Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2019 18,536
PMTCT_EID By infants who received a virologic test within 2 months of birth 2019 3,240
PMTCT_EID By infants who received their first virologic HIV test between 2 and 12 months of age 2019 928
PMTCT_EID Number of infants who had a virologic HIV test within 12 months of birth during the reporting period 2019 4,168
PMTCT_EID Sum of Infant Age disaggregates 2019 4,168
PMTCT_STAT 25-29, Female 2019 4,769
PMTCT_STAT 25-29, Female, Known at Entry Positive 2019 759
PMTCT_STAT 25-29, Female, Newly Identified Negative 2019 3,692
PMTCT_STAT 25-29, Female, Newly Identified Positive 2019 316
PMTCT_STAT 30-34, Female 2019 3,732
PMTCT_STAT 30-34, Female, Known at Entry Positive 2019 977
PMTCT_STAT 30-34, Female, Newly Identified Negative 2019 2,574
PMTCT_STAT 30-34, Female, Newly Identified Positive 2019 189
PMTCT_STAT 35-39, Female 2019 2,342
PMTCT_STAT 35-39, Female, Known at Entry Positive 2019 826
PMTCT_STAT 35-39, Female, Newly Identified Negative 2019 1,380
PMTCT_STAT 35-39, Female, Newly Identified Positive 2019 140
PMTCT_STAT 40-49, Female 2019 742
PMTCT_STAT 40-49, Female, Known at Entry Positive 2019 330
PMTCT_STAT 40-49, Female, Newly Identified Negative 2019 366
PMTCT_STAT 40-49, Female, Newly Identified Positive 2019 38
PMTCT_STAT By Age (Numerator): : 15-19 2019 1,851
PMTCT_STAT By Age (Numerator): 10-14 2019 2
PMTCT_STAT By Age (Numerator): 20-24 2019 5,085
PMTCT_STAT By known positives: 15-19 2019 90
PMTCT_STAT By known positives: 20-24 2019 408
PMTCT_STAT By new negatives: 10-14 2019 1
PMTCT_STAT By new negatives: 15-19 2019 1,706
PMTCT_STAT By new negatives: 20-24 2019 4,412
PMTCT_STAT By new positives: 15-19 2019 43
PMTCT_STAT By new positives: 20-24 2019 268
PMTCT_STAT Number of new ANC and L&D clients 2019 19,496
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2019 18,536
PMTCT_STAT_den 25-29, Female 2019 5,095
PMTCT_STAT_den 30-34, Female 2019 3,908
PMTCT_STAT_den 35-39, Female 2019 2,402
PMTCT_STAT_den 40-49, Female 2019 740
PMTCT_STAT_den By Age (Denominator): 10-14 2019 4
PMTCT_STAT_den By Age (Denominator): 15-19 2019 1,922
PMTCT_STAT_den By Age (Denominator): 20-24 2019 5,425
TX_CURR 25-29, Female, Positive 2019 12,241
TX_CURR 25-29, Male, Positive 2019 6,134
TX_CURR 30-34, Female, Positive 2019 17,312
TX_CURR 30-34, Male, Positive 2019 9,871
TX_CURR 35-39, Female, Positive 2019 20,332
TX_CURR 35-39, Male, Positive 2019 12,980
TX_CURR 40-49, Female, Positive 2019 29,533
TX_CURR 40-49, Male, Positive 2019 23,482
TX_CURR Age/Sex: <1 2019 206
TX_CURR Age/Sex: 1-9 2019 2,638
TX_CURR Age/Sex: 10-14 Female 2019 986
TX_CURR Age/Sex: 10-14 Male 2019 1,052
TX_CURR Age/Sex: 15-19 Female 2019 3,779
TX_CURR Age/Sex: 15-19 Male 2019 2,218
TX_CURR Age/Sex: 20-24 Female 2019 7,849
TX_CURR Age/Sex: 20-24 Male 2019 3,519
TX_CURR Age/Sex: 50+ Female 2019 23,325
TX_CURR Age/Sex: 50+ Male 2019 19,940
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2019 197,401
TX_CURR Sum of Age/Sex disaggregations 2019 5,997
TX_NEW 25-29, Female, Positive 2019 1,506
TX_NEW 25-29, Male, Positive 2019 1,216
TX_NEW 30-34, Female, Positive 2019 1,533
TX_NEW 30-34, Male, Positive 2019 970
TX_NEW 35-39, Female, Positive 2019 2,737
TX_NEW 35-39, Male, Positive 2019 1,591
TX_NEW 40-49, Female, Positive 2019 6,591
TX_NEW 40-49, Male, Positive 2019 4,980
TX_NEW By Age/Sex: <1 2019 205
TX_NEW By Age/Sex: 1-9 2019 368
TX_NEW By Age/Sex: 15-19 Female 2019 413
TX_NEW By Age/Sex: 20-24 Female 2019 1,293
TX_NEW By Age/Sex: 20-24 Male 2019 995
TX_NEW By Age/Sex: 50+ Female 2019 5,671
TX_NEW By Age/Sex: 50+ Male 2019 5,331
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2019 35,406
TX_NEW Sum of Age/Sex disaggregates 2019 13,703
TX_PVLS Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months 2019 159,480
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Female Routine 2019 1,224
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted 2019 52
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Male Routine 2019 1,098
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted 2019 52
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine 2019 99,697
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted 2019 2,964
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine 2019 52,701
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted 2019 1,757
TX_RET Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2019 365
TX_RET Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2019 253
TX_RET Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2019 20,434
TX_RET Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2019 14,198
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2019 35,247
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2019 36,997
TX_RET_den Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2019 383
TX_RET_den Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2019 270
TX_RET_den Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2019 21,454
TX_RET_den Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2019 14,908
TX_TB Number of ART patients who were screened for TB at least once during the reporting period 2019 194,566
TX_TB Number of ART patients who were started on TB treatment during the reporting period 2019 264
TX_TB Numerator: By Aggregated Age/Sex: 15+, Female 2019 152
TX_TB Numerator: By Aggregated Age/Sex: 15+, Male 2019 109
TX_TB_den Denominator: By Aggregated Age/Sex: <15, Female 2019 986
TX_TB_den Denominator: By Aggregated Age/Sex: <15, Male 2019 1,053
TX_TB_den Denominator: By Aggregated Age/Sex: 15+, Female 2019 114,374
TX_TB_den Denominator: By Aggregated Age/Sex: 15+, Male 2019 78,151
TX_TB_den Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay 2019 375
TX_TB_den Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert) 2019 1,569
TX_TB_den Denominator: By Specimen Sent: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease 2019 1,944
Cross Cutting Budget Categories and Known Amounts Total: $480,000
Adolescent Girls and Young Women (AGYW) $400,000
Motor Vehicles: Purchased $80,000